Create Free Account

By creating account you will get access to hot stocks & personalised emails

Clarity Pharmaceuticals Ltd

Healthcare AU CU6

4.97AUD
-0.2(3.87%)

Last update at 2024-12-19T05:11:00Z

Day Range

4.915.32
LowHigh

52 Week Range

1.648.97
LowHigh

Fundamentals

  • Previous Close 5.17
  • Market Cap1458.93M
  • Volume1524324
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-44.64759M
  • Revenue TTM11.51M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 9.80M
  • Diluted EPS TTM-0.16

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -24.49925M -23.73695M -10.22137M -6.95386M -
Minority interest - - - - -
Net income -24.60245M -23.75458M -10.22137M -6.95386M -
Selling general administrative 4.71M 9.07M 3.82M 2.80M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.10M 0.05M - - -
Ebit -26.36351M -30.29097M -10.31330M -7.05729M -3.76563M
Ebitda -36.06355M -30.24472M - - -
Depreciation and amortization - 0.05M - - -
Non operating income net other - - - - -
Operating income -24.49924M -30.29097M -10.22132M -6.94787M -
Other operating expenses - 30.29M - - 0.78M
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision 0.10M 0.02M 0.00000M 0.00000M -
Interest income 1.86M 0.10M 0.00005M 0.00599M -
Net interest income 1.86M 0.10M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.10M 0.02M - - -
Total revenue 11.66M 6.55M 3.29M 2.90M -
Total operating expenses - 30.29M - - -
Cost of revenue - - - - -
Total other income expense net 9.80M 6.46M - - -
Discontinued operations - - - - -
Net income from continuing ops -24.60245M -23.75458M - - -
Net income applicable to common shares -24.60245M -23.75458M -10.22137M -6.95386M -3.68433M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 154.63M 76.90M 99.82M 22.61M 9.12M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 4.92M - - - -
Total liab 8.33M 7.72M 7.59M 2.34M 0.96M
Total stockholder equity 146.30M 69.18M 92.24M 20.28M 8.16M
Deferred long term liab - - - - -
Other current liab 6.00M 0.48M 4.66M 0.84M 0.41M
Common stock 249.45M 132.82M 132.12M 44.90M 23.93M
Capital stock - 132.82M 132.12M - -
Retained earnings -112.69870M -70.37427M -45.79569M -28.84960M -18.86558M
Other liab - 0.18M 0.08M 0.08M 0.00915M
Good will - - - - -
Other assets - 0.01M 0.01M 0.01M 0.01M
Cash 136.51M 5.97M 55.34M 8.44M 5.27M
Cash and equivalents - 25.24M 25.00M - -
Total current liabilities 8.09M 7.54M 7.51M 2.25M 0.95M
Current deferred revenue - - - - -
Net debt -136.50566M - -55.33633M - -
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 6.73M 5.92M 4.22M 3.09M
Property plant equipment - 0.21M 0.26M 0.09M 0.05M
Total current assets 154.06M 76.68M 99.55M 22.51M 9.05M
Long term investments - 0.01M 0.01M - -
Net tangible assets - 69.18M 92.24M 20.28M 8.16M
Short term investments - 33.80M 37.00M 10.50M 1.00M
Net receivables 12.63M 10.00M 6.66M 3.37M 2.66M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.08M 2.85M 2.85M 0.23M 0.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 9.55M - 5.92M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.57M 0.22M 0.27M - -
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 3.20M -26.50036M -9.50000M -9.50000M -9.50000M
Change to liabilities 0.02M 4.93M 1.04M -0.28311M 0.19M
Total cashflows from investing activities 3.15M -26.71351M -9.56031M -0.01450M -0.01567M
Net borrowings - - - - -
Total cash from financing activities 0.23M 86.93M 20.41M 8.22M 5.93M
Change to operating activities -0.92263M -0.01123M 0.13M 0.12M -0.07063M
Net income -24.60245M -23.75458M -10.22137M -6.95386M -3.68433M
Change in cash -24.12324M 46.90M 3.17M 1.37M 2.21M
Begin period cash flow 55.34M 8.44M - - -
End period cash flow 31.21M 55.34M 8.44M - -
Total cash from operating activities -27.49996M -13.31392M -7.67708M -6.83030M -3.70693M
Issuance of capital stock 0.18M 92.40M - - -
Depreciation 0.10M 0.05M 0.02M 0.02M 0.02M
Other cashflows from investing activities 3.20M -26.50037M -9.50000M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -3.34464M -3.28566M -0.71229M -0.92392M -0.68907M
Sale purchase of stock 0.24M -5.60315M 21.10M 4.70M -
Other cashflows from financing activities -0.01275M 0.13M -0.68122M 3.51M -4.52265M
Change to netincome 1.25M 8.77M 2.07M 1.19M 0.52M
Capital expenditures 0.05M 0.21M 0.06M 0.01M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 8.31M 3.34M 2.56M 2.01M -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -27.54652M -0.21315M - - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CU6
Clarity Pharmaceuticals Ltd		 -0.2 3.87% 4.97 - - 126.79 11.33 - -0.7791
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd

National Innovation Centre, Sydney, NSW, Australia, 2015

Key Executives

Name Title Year Born
Dr. Alan John Taylor Ph.D. Exec. Chairman NA
Dr. Colin David Biggin Ph.D. MD, CEO & Exec. Director NA
Mr. David K. Green BEc., CA Chief Financial Officer NA
Mr. Robert Vickery Company Sec. NA
Dr. Michael D. Ironside Director of Operations NA
Dr. Jeffrey Norenberg Chief Scientific Officer NA
Dr. Ellen van Dam Ph.D. Head of R&D NA
Mr. Shaemus Gleason Exec. VP of US Operations NA
Dr. Robert M. Miller Ph.D. Consultant Chief Medical Officer 1952
Mr. William Cheadle Financial Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.